Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

360 ARTÍCULOS , VIENDO DEL 151 AL 165

Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease

Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, Melchiorre C.

Curr Top Med Chem. 2011 Nov;11(22):2797-806. doi: 10.2174/156802611798184373.

1,8-Naphthyridine derivatives as cholinesterases inhibitors and cell Ca2+ regulators, a multitarget strategy for Alzheimer's disease

Egea J, de los Rios C.

Curr Top Med Chem. 2011 Nov;11(22):2807-23. doi: 10.2174/156802611798184418.

Multi-target-directed ligands in Alzheimer's disease treatment

Bajda M, Guzior N, Ignasik M, Malawska B.

Curr Med Chem. 2011;18(32):4949-75. doi: 10.2174/092986711797535245.

Challenges associated with curcumin therapy in Alzheimer disease

Belkacemi A, Doggui S, Dao L, Ramassamy C.

Expert Rev Mol Med. 2011 Nov 4;13:e34. doi: 10.1017/S1462399411002055.

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type

Dhillon S.

Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000.

Long-term progression of Alzheimer's disease in patients under antidementia drugs

Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B; REAL.FR study group.

Alzheimers Dement. 2011 Nov;7(6):579-92. doi: 10.1016/j.jalz.2011.02.009.

Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders

Cecon E, Markus RP.

Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):91-9. doi: 10.2174/187221411799015381.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. doi: 10.2174/092986711798194351.

Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease

Marcus JN, Schachter J.

J Neurogenet. 2011 Dec;25(4):127-33. doi: 10.3109/01677063.2011.626471.

Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease

Percy ME, Kruck TP, Pogue AI, Lukiw WJ.

J Inorg Biochem. 2011 Nov;105(11):1505-12. doi: 10.1016/j.jinorgbio.2011.08.001. Epub 2011 Aug 19.

Toward a unifying hypothesis in the development of Alzheimer's disease

Balin B, Abrams JT, Schrogie J.

CNS Neurosci Ther. 2011 Dec;17(6):587-9. doi: 10.1111/j.1755-5949.2011.00269.x.

Testing the right target and right drug at the right stage

Sperling RA, Jack CR Jr, Aisen PS.

Sci Transl Med. 2011 Nov 30;3(111):111cm33. doi: 10.1126/scitranslmed.3002609.

Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease

Cuadrado-Tejedor M, García-Osta A, Ricobaraza A, Oyarzabal J, Franco R.

Curr Med Chem. 2011;18(36):5545-53. doi: 10.2174/092986711798347315.

The beneficial role of vitamin D in Alzheimer's disease

Lu'o'ng KV, Nguyên LT.

Am J Alzheimers Dis Other Demen. 2011 Nov;26(7):511-20. doi: 10.1177/1533317511429321. Epub 2011 Dec 27.

Management of moderate to severe Alzheimer's disease: focus on memantine

Dominguez E, Chin TY, Chen CP, Wu TY.

Taiwan J Obstet Gynecol. 2011 Dec;50(4):415-23. doi: 10.1016/j.tjog.2011.10.004.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias